MedPath

Effect of vitamin D supplement in regulation of blood pressure

Phase 3
Conditions
Essential hypertension.
Essential (primary) hypertension
Registration Number
IRCT20080901001165N57
Lead Sponsor
Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
200
Inclusion Criteria

Essential Hypertension (Systolic pressure > 140 mmHg, Diastolic pressure > 90 mmHg)
Adult patients from 18 to 65 y/o
Patients under standard Anti-hypertensive agents
Vitamin D level is less than 30.

Exclusion Criteria

Heart Failure (LVEF<45%)
Renal Failure (Creatinine>1.5mg/dl)
Hepatic Failure
Chronic Obstructive Pulmonary Disease (COPD): (FEV1/FVC <70%)
Thyroid disorders
Hyperparathyroidism
Systemic infection
Hypercalciurea

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Systolic blood pressure. Timepoint: at baseline and 8 weeks after intervention. Method of measurement: Sphygmomanometer, mmHg.;Diastolic blood pressure. Timepoint: at baseline and 8 weeks after intervention. Method of measurement: Sphygmomanometer, mmHg.;Mean arterial pressure. Timepoint: at baseline and 8 weeks after intervention. Method of measurement: Sphygmomanometer, mmHg.;Vitamin D serum level. Timepoint: at baseline and 8 weeks after intervention. Method of measurement: ng/ml.
Secondary Outcome Measures
NameTimeMethod
Adverse effect of vitamin D supplement. Timepoint: 8 weeks after treatment. Method of measurement: Questionnaire.
© Copyright 2025. All Rights Reserved by MedPath